Precision Conjugation: One Antibody, One Step, Multiple Payloads
11:45 am - Wednesday 10th March 2027
- Presenting AraLinQ™ ADCs: ADCs targeting solid and liquid tumours, including clinical-stage ARC-02
- Highlighting Efficacy and Tolerability: Preclinical data demonstrating strong anti-tumour efficacy and high tolerability across multiple models
- Overcoming conventional ADC limitations: Addressing payload loss and narrow therapeutic windows through differentiated ADC design and multipayload approaches
